Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Maher

Showing results (1071-1080 of 1,158) with videos related to

Pageof 116
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|December 10, 2019
Clinical quantification of the integrin αvβ6 by [<sup>18</sup>F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)Pauline T Lukey, Christopher Coello, Roger Gunn, et al.
Clinical Rheumatology|January 10, 2020
Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung diseaseCarmel J W Stock, Angelo De Lauretis, Dina Visca, et al.
The Journal of Experimental Medicine|January 10, 2020
Dynamics of human monocytes and airway macrophages during healthy aging and after transplantAdam J Byrne, Joseph E Powell, Brendan J O'Sullivan, et al.
American Journal of Respiratory and Critical Care Medicine|June 18, 2014
Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumoniaTamera J Corte, Gregory J Keir, Konstantinos Dimopoulos, et al.
Respiratory Research|July 14, 2019
Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohortLouise A Organ, Anne-Marie R Duggan, Eunice Oballa, et al.
The New England Journal of Medicine|May 19, 2025
Nerandomilast in Patients with Progressive Pulmonary FibrosisToby M Maher, Shervin Assassi, Arata Azuma, et al.
Science Immunology|October 24, 2020
Itaconate controls the severity of pulmonary fibrosisPatricia P Ogger, Gesa J Albers, Richard J Hewitt, et al.
American Journal of Respiratory and Critical Care Medicine|March 10, 2021
Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer CellsYong Huang, Justin M Oldham, Shwu-Fan Ma, et al.
Thorax|April 23, 2016
Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPFPaul F Mercer, Hannah V Woodcock, Jessica D Eley, et al.
Thorax|June 19, 2025
Basement membrane repair response biomarker PRO-C4 predicts progression in idiopathic pulmonary fibrosis: analysis of the PFBIO and PROFILE cohortsJannie M B Sand, Peder Frederiksen, Alison E John, et al.
Pageof 116

Showing results (1071-1080 of 1,158) with videos related to

Sort By:
Pageof 116
European Journal of Nuclear Medicine and Molecular Imaging|December 10, 2019
Clinical quantification of the integrin αvβ6 by [<sup>18</sup>F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)Pauline T Lukey, Christopher Coello, Roger Gunn, et al.
Clinical Rheumatology|January 10, 2020
Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung diseaseCarmel J W Stock, Angelo De Lauretis, Dina Visca, et al.
The Journal of Experimental Medicine|January 10, 2020
Dynamics of human monocytes and airway macrophages during healthy aging and after transplantAdam J Byrne, Joseph E Powell, Brendan J O'Sullivan, et al.
American Journal of Respiratory and Critical Care Medicine|June 18, 2014
Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumoniaTamera J Corte, Gregory J Keir, Konstantinos Dimopoulos, et al.
Respiratory Research|July 14, 2019
Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohortLouise A Organ, Anne-Marie R Duggan, Eunice Oballa, et al.
The New England Journal of Medicine|May 19, 2025
Nerandomilast in Patients with Progressive Pulmonary FibrosisToby M Maher, Shervin Assassi, Arata Azuma, et al.
Science Immunology|October 24, 2020
Itaconate controls the severity of pulmonary fibrosisPatricia P Ogger, Gesa J Albers, Richard J Hewitt, et al.
American Journal of Respiratory and Critical Care Medicine|March 10, 2021
Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer CellsYong Huang, Justin M Oldham, Shwu-Fan Ma, et al.
Thorax|April 23, 2016
Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPFPaul F Mercer, Hannah V Woodcock, Jessica D Eley, et al.
Thorax|June 19, 2025
Basement membrane repair response biomarker PRO-C4 predicts progression in idiopathic pulmonary fibrosis: analysis of the PFBIO and PROFILE cohortsJannie M B Sand, Peder Frederiksen, Alison E John, et al.
Pageof 116